NO321096B1 - Fremgangsmate for forbedring av in vivo-funksjonen av rekombinant faktor VIII SQ ved a skjerme utsatte mal pa polypeptidet - Google Patents

Fremgangsmate for forbedring av in vivo-funksjonen av rekombinant faktor VIII SQ ved a skjerme utsatte mal pa polypeptidet Download PDF

Info

Publication number
NO321096B1
NO321096B1 NO19981408A NO981408A NO321096B1 NO 321096 B1 NO321096 B1 NO 321096B1 NO 19981408 A NO19981408 A NO 19981408A NO 981408 A NO981408 A NO 981408A NO 321096 B1 NO321096 B1 NO 321096B1
Authority
NO
Norway
Prior art keywords
factor viii
factor
mpeg
polypeptide
viii
Prior art date
Application number
NO19981408A
Other languages
English (en)
Norwegian (no)
Other versions
NO981408L (no
NO981408D0 (no
Inventor
Eva Akerblom
Johanna Dalborg
Helena Sandberg
Anna-Lisa Smeds
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20399642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO321096(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO981408L publication Critical patent/NO981408L/no
Publication of NO981408D0 publication Critical patent/NO981408D0/no
Publication of NO321096B1 publication Critical patent/NO321096B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Polyamides (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19981408A 1995-09-29 1998-03-27 Fremgangsmate for forbedring av in vivo-funksjonen av rekombinant faktor VIII SQ ved a skjerme utsatte mal pa polypeptidet NO321096B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9503380A SE9503380D0 (sv) 1995-09-29 1995-09-29 Protein derivatives
PCT/SE1996/001215 WO1997011957A1 (fr) 1995-09-29 1996-09-27 Conjugues d'un polypeptide et d'un polymere biocompatible

Publications (3)

Publication Number Publication Date
NO981408L NO981408L (no) 1998-03-27
NO981408D0 NO981408D0 (no) 1998-03-27
NO321096B1 true NO321096B1 (no) 2006-03-13

Family

ID=20399642

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19981408A NO321096B1 (no) 1995-09-29 1998-03-27 Fremgangsmate for forbedring av in vivo-funksjonen av rekombinant faktor VIII SQ ved a skjerme utsatte mal pa polypeptidet
NO20051950A NO20051950L (no) 1995-09-29 2005-04-21 Konjugater av et polypeptid og en biokompatibel polymer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20051950A NO20051950L (no) 1995-09-29 2005-04-21 Konjugater av et polypeptid og en biokompatibel polymer

Country Status (18)

Country Link
US (1) US6048720A (fr)
EP (3) EP1258497B1 (fr)
JP (1) JP3911023B2 (fr)
AT (3) ATE283351T1 (fr)
AU (1) AU706246B2 (fr)
BR (1) BR9610695A (fr)
CA (1) CA2231801C (fr)
DE (3) DE69633952T2 (fr)
DK (3) DK1258497T3 (fr)
ES (3) ES2236396T3 (fr)
HU (1) HU221208B1 (fr)
NO (2) NO321096B1 (fr)
NZ (1) NZ319322A (fr)
PL (1) PL185821B1 (fr)
PT (3) PT871649E (fr)
SE (1) SE9503380D0 (fr)
WO (1) WO1997011957A1 (fr)
ZA (1) ZA968139B (fr)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
CZ298579B6 (cs) 1998-04-28 2007-11-14 Applied Research Systems Ars Holding N. V. Konjugát polyolu a interferonu-beta
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
EP1154796B1 (fr) 1999-02-22 2007-06-20 University of Connecticut Nouvelles formulations de facteur viii sans albumine
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
IT1318484B1 (it) * 2000-04-21 2003-08-25 Univ Roma Derivati di colina per il trattamento della malattia di alzheimer.
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) * 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
WO2002004483A1 (fr) * 2000-07-07 2002-01-17 Samokhin Gennady P Conjugues proteiniques biologiquement actifs formes par une protection initiale de site actif
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
JP2010209109A (ja) * 2001-06-25 2010-09-24 Regents Of The Univ Of Michigan 抗微生物ナノエマルジョンの組成物および方法
CA2452582C (fr) * 2001-07-11 2013-01-22 Maxygen Holdings, Ltd. Conjugues de g-csf
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
SG159381A1 (en) * 2001-10-10 2010-03-30 Novo Nordisk As Remodeling and glycoconjugation of peptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
SE0104186D0 (sv) * 2001-12-12 2001-12-12 Darcy Birse Method and device
EP3669887A1 (fr) * 2002-01-18 2020-06-24 Biogen MA Inc. Composés polymères de polyalkylène et leurs utilisations
US20030149246A1 (en) * 2002-02-01 2003-08-07 Russell John C. Macromolecular conjugates and processes for preparing the same
US20050153416A1 (en) * 2002-03-02 2005-07-14 Nikolaos Dimoudis Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
ES2911435T3 (es) * 2003-02-26 2022-05-19 Nektar Therapeutics Conjugados de polímero-resto de Factor VIII
WO2004103270A2 (fr) * 2003-04-02 2004-12-02 Suntory Pharmaceutical Research Laboratories Llc Composes et procedes destines au traitement de la thrombose
WO2006127896A2 (fr) * 2005-05-25 2006-11-30 Neose Technologies, Inc. Facteur ix glycopegyle
EP1615945B1 (fr) 2003-04-09 2011-09-28 BioGeneriX AG Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1626983B8 (fr) * 2003-05-12 2010-12-22 Affymax, Inc. Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
TR201907313T4 (tr) * 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
US20050171002A1 (en) * 2004-02-03 2005-08-04 Mohanty Dillip K. Polyoxyalkylene compound and method for making
AU2005228945B2 (en) 2004-03-19 2010-09-30 Baxter Healthcare S.A. Factor IXa for the treatment of bleeding disorders
KR20070027621A (ko) * 2004-06-08 2007-03-09 알자 코포레이션 4-성분 축합 반응에 의한 고분자 콘쥬게이트의 제조
KR101100059B1 (ko) * 2004-06-30 2011-12-29 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
AU2005292135B2 (en) * 2004-09-29 2011-09-29 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitits C virus
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
AU2012203813B2 (en) * 2004-11-12 2013-10-24 Bayer Healthcare Llc Site-directed modification of FVIII
KR101654011B1 (ko) * 2004-11-12 2016-09-05 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
AU2013203348B2 (en) * 2004-11-12 2016-03-03 Bayer Healthcare Llc Site-directed modification of FVIII
AU2005332660A1 (en) * 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
AU2016203693B2 (en) * 2004-11-12 2018-08-23 Bayer Healthcare Llc Site-directed modification of FVIII
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
WO2006076471A2 (fr) * 2005-01-12 2006-07-20 Nobex Corporation Conjugues bnp et procedes d'utilisation
WO2006121569A2 (fr) * 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions et methodes utilisees pour la preparation de mutants par glycosylation de l'hormone de croissance humaine resistant a la protease
EP2722051B1 (fr) 2005-07-07 2018-11-07 Seattle Genetics, Inc. Composés de monométhylvaline présentant des modifications de la chaîne latérale de phénylalanine au niveau de la terminaison C
US8871720B2 (en) * 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
US7395967B2 (en) * 2005-07-21 2008-07-08 University Of Washington Methods and systems for counterbalancing a scanning beam device
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
JP2009532351A (ja) * 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
ES2516694T3 (es) * 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
KR101556248B1 (ko) * 2006-10-04 2015-09-30 노보 노르디스크 에이/에스 글리세롤이 연결된 페길화된 당 및 글리코펩티드
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
MX2009007146A (es) * 2006-12-27 2009-07-09 Nektar Therapeutics Al Corp Conjugados porcion del factor ix-polimero que tienen ligadura que se puede liberar.
JP5702066B2 (ja) 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
CN103990116A (zh) * 2007-04-26 2014-08-20 拜尔健康护理有限责任公司 稳定用于冷冻储藏的重组蛋白液体溶液的方法
US8747872B2 (en) 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
EP2167117B1 (fr) * 2007-06-13 2012-08-15 CSL Behring GmbH Utilisation de préparations stabilisées du vwf avec du fviii destinées à une administration extra-vasculaire dans la thérapie et le traitement prophylactique de troubles de saignements
PE20090481A1 (es) 2007-07-16 2009-05-18 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
CN111499748A (zh) 2007-07-16 2020-08-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
US8173597B2 (en) * 2007-11-09 2012-05-08 Baxter International Inc. Modified recombinant factor VIII and von Willebrand factor and methods of use
EP3269737B1 (fr) 2008-01-31 2024-06-19 Genentech, Inc. Anticorps anti-cd79b et immuno-conjugués et procédés d'utilisation
WO2009108806A1 (fr) 2008-02-27 2009-09-03 Novo Nordisk A/S Molécules de facteur viii conjuguées
EP2297330A4 (fr) * 2008-06-04 2012-03-14 Bayer Healthcare Llc Mutéines du facteur viii pour le traitement de la maladie de von willebrand
EP2291523B1 (fr) 2008-06-24 2014-12-17 CSL Behring GmbH Facteur VIII, facteur von Willebrand ou complexes associés avec demi-vie in vivo prolongée
WO2010045321A2 (fr) * 2008-10-15 2010-04-22 Baxter International Inc. Pégylation de facteurs de coagulation sanguine recombinants en présence d’anticorps liés
EP2352515A4 (fr) * 2008-11-03 2012-04-25 Bayer Healthcare Llc Procédé de traitement de l'hémophilie
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
CA2743904A1 (fr) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Compositions de vaccins contre le cancer et leurs methodes d'utilisation
WO2010091122A1 (fr) 2009-02-03 2010-08-12 Amunix, Inc. Polypeptides recombinants étendus et compositions les comprenant
CA2769244A1 (fr) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glyco-polysialylation de proteines de coagulation non sanguine
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2459224B1 (fr) 2009-07-27 2016-06-01 Baxalta GmbH Conjugués de protéine de coagulation sanguine
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
HUE036233T2 (hu) 2009-12-06 2018-06-28 Bioverativ Therapeutics Inc VIII-FC Faktor kimérás és hibrid polipeptidek, és ezek használati módszerei
EP2552967A4 (fr) 2010-04-02 2014-10-08 Amunix Operating Inc Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP3508573A1 (fr) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systèmes de traitement de facteur viii et procédés associés
KR20140002601A (ko) 2010-07-09 2014-01-08 바이오겐 이데크 헤모필리아 인코포레이티드 키메라 응고 인자
KR20130125789A (ko) * 2010-12-16 2013-11-19 노보 노르디스크 에이/에스 수성 인자ⅷ 용액
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
EP3527218A1 (fr) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Composés procoagulants et procédés d'utilisation correspondants
EP4169525A1 (fr) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Polypeptides chimériques et hybrides de facteur viii et leurs procédés d'utilisation
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EA029560B1 (ru) 2012-01-12 2018-04-30 Байоджен Эмэй Инк. Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
LT2814840T (lt) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
EP2822577B1 (fr) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Protéines de facteur viii de recombinaison
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
WO2013130683A2 (fr) 2012-02-27 2013-09-06 Amunix Operating Inc. Compositions de conjugués xten et leurs procédés de préparation
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
WO2013185114A2 (fr) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Facteurs de coagulation chimériques
EP4079316A1 (fr) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Composés procoagulants
EP3404105A1 (fr) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Lignée cellulaire exprimant des polypeptides du facteur viii à chaîne unique et ses utilisations
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (fr) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
EP2914293A4 (fr) 2012-10-30 2016-04-20 Biogen Ma Inc Procédés d'utilisation du polypeptide fviii
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
DK3889173T3 (da) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
MX2015016567A (es) 2013-06-28 2016-03-31 Biogen Ma Inc Enlazador escindible por trombina con xten y usos del mismo.
EP3043813B1 (fr) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Purification de molécules chimères du facteur viii
EP3033097B1 (fr) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Fusions de factor viii-xten et leurs utilisations.
WO2015070014A1 (fr) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Composé de fusion procoagulant
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
DK4176894T3 (da) 2014-01-10 2024-05-27 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
KR20230136616A (ko) 2014-02-04 2023-09-26 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
EP3164150B1 (fr) 2014-07-02 2020-11-04 CSL Behring Lengnau AG Facteur de von willebrand modifié
CA3069221C (fr) 2014-09-23 2023-04-04 Genentech, Inc. Methodes d'utilisation d'immunoconjugues anti-cd79b
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
KR20170125941A (ko) 2015-03-06 2017-11-15 체에스엘 베링 리컴비넌트 퍼실리티 아게 개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
EP3298036B1 (fr) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Procédés de préparation du facteur willebrand modifié
RU2017145014A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Усеченные полипептиды фактора фон виллебранда для лечения гемофилии
CA2991973C (fr) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Lieurs de pontage pour la conjugaison d'une molecule de liaison cellulaire
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
AU2016353353B2 (en) 2015-11-13 2020-07-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
CA3005565A1 (fr) 2015-11-13 2017-05-18 Baxalta Incorporated Vecteurs viraux codant pour des variants du facteur viii de recombinaison avec une expression augmentee pour la therapie genique de l'hemophilie a
MX2018008337A (es) 2016-01-07 2018-09-17 CSL Behring Lengnau AG Factor de von willebrand truncado mutado.
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
PT3411478T (pt) 2016-02-01 2022-09-13 Bioverativ Therapeutics Inc Genes do fator viii otimizados
EP3476937A4 (fr) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research Protéine chimère comprenant les facteurs fviii et vwf, et utilisation de celle-ci
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
EP3538133B1 (fr) 2016-11-11 2021-02-17 CSL Behring Lengnau AG Polypeptides du facteur von willebrand tronqués pour traiter l'hémophilie
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
EP3548066A1 (fr) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
BR112020015228A2 (pt) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. Uso de vetores lentivirais que expressam fator viii
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
MX2021000582A (es) 2018-07-16 2021-04-12 Baxalta Inc Terapia genica de hemofilia a mediante el uso de vectores virales que codifican variantes del factor viii (fviii) recombinantes con mayor expresion.
MX2021001599A (es) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Moleculas de acido nucleico y sus usos para la terapia genica no viral.
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
EP3986444A1 (fr) 2019-06-19 2022-04-27 Bioverativ Therapeutics Inc. Facteur viii-fc recombinant pour traiter l'hémophilie et la faible densité minérale osseuse
EP4073106A2 (fr) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Thérapie génique de l'hémophilie à l'aide de vecteurs viraux codant des variants de fviii recombinants présentant une expression accrue
EP4355768A1 (fr) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Thérapie génique contre l'hémophilie a faisant appel à des vecteurs viraux codant pour des variants de fviii recombinés à expression accrue
AU2022332276A1 (en) 2021-08-23 2024-04-04 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2023056331A1 (fr) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Acides nucléiques codant pour des polypeptides du facteur viii à immunogénicité réduite
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE3717210C2 (de) * 1987-05-22 1993-11-25 Diagen Inst Molekularbio Verfahren zur Modifizierung von Nukleinsäuren
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
WO1992016555A1 (fr) * 1991-03-18 1992-10-01 Enzon, Inc. Conjuges de polypeptides et de glycopolypeptides associes a des polymeres, contenant de l'hydrazine
US5169627A (en) * 1991-10-28 1992-12-08 Mount Sinai School Of Medicine Of The City University Of New York Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
WO1994015625A1 (fr) * 1993-01-15 1994-07-21 Enzon, Inc. Conjugues de polymere et de facteur viii
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates

Also Published As

Publication number Publication date
DE69625085T2 (de) 2003-07-17
EP1260582B1 (fr) 2004-11-24
ZA968139B (en) 1997-05-29
BR9610695A (pt) 1999-07-06
ES2236396T3 (es) 2005-07-16
EP1260582A1 (fr) 2002-11-27
HUP9901203A3 (en) 2000-02-28
CA2231801A1 (fr) 1997-04-03
US6048720A (en) 2000-04-11
EP0871649A1 (fr) 1998-10-21
PL325958A1 (en) 1998-08-17
DE69633952D1 (de) 2004-12-30
HUP9901203A2 (hu) 1999-07-28
DK1258497T3 (da) 2005-06-06
EP1258497B1 (fr) 2005-02-16
SE9503380D0 (sv) 1995-09-29
EP1258497A2 (fr) 2002-11-20
DE69633952T2 (de) 2006-03-02
ATE289321T1 (de) 2005-03-15
NO981408L (no) 1998-03-27
PT1258497E (pt) 2005-06-30
NO981408D0 (no) 1998-03-27
ATE283351T1 (de) 2004-12-15
DK0871649T3 (da) 2003-03-24
EP0871649B1 (fr) 2002-11-27
NZ319322A (en) 1998-08-26
ATE228531T1 (de) 2002-12-15
CA2231801C (fr) 2010-07-27
HU221208B1 (en) 2002-08-28
PT871649E (pt) 2003-04-30
JPH11513378A (ja) 1999-11-16
DK1260582T3 (da) 2005-03-29
NO20051950L (no) 1998-03-27
ES2187676T3 (es) 2003-06-16
PL185821B1 (pl) 2003-08-29
DE69634373T2 (de) 2005-12-29
AU706246B2 (en) 1999-06-10
PT1260582E (pt) 2005-03-31
AU7151796A (en) 1997-04-17
WO1997011957A1 (fr) 1997-04-03
DE69634373D1 (de) 2005-03-24
JP3911023B2 (ja) 2007-05-09
EP1258497A3 (fr) 2002-11-27
DE69625085D1 (de) 2003-01-09
ES2238522T3 (es) 2005-09-01

Similar Documents

Publication Publication Date Title
US6048720A (en) Conjugates of a polypeptide and a biocompatible polymer
CN103214569B (zh) Fviii的位点定向修饰
US5854403A (en) Method for isolation of highly pure von Willebrand Factor
US20120121613A1 (en) Protein conjugate having an endopeptidase- cleavable bioprotective moiety
EP0573605A1 (fr) Preparation de facteur ix
AU611932B2 (en) Novel complex
MXPA98002416A (es) Conjugados de un polipeptido y un polimero biocompatible
AU2016203693B2 (en) Site-directed modification of FVIII
MXPA99008941A (es) Preparacion del complejo de protrombina inmunotolerante

Legal Events

Date Code Title Description
MK1K Patent expired